Earlier this week, MaxCyte’s director of technical operations, Robert Keefe, gave a speech at the American Society of Gene and Cell Therapy.
He highlighted the potential to manufacture drug candidates on the platform within a day, providing a much-needed faster turnaround of autologous cell therapy to patients.
Keefe also discussed the manufacturing feasibility data for MaxCyte’s first CARMA drug candidate, MCY-M11, which is currently undergoing a phase I study in 15 women with ovarian cancer and peritoneal mesothelioma.
“The advancement of our first CARMA clinical trial, which is consistently showing the feasibility of our rapid manufacturing process, is significant for MaxCyte and the application of our technology,” said chief medical officer Claudio Dansky Ullmann.
“Development of a cell therapy with application in solid tumours is impactful for patients with unmet needs in a variety of cancers and we look forward to further advancing this program.”